Wyeth Pharmaceuticals, a subsidiary of Pfizer, was charged with illegally marketing a drug that was not cleared for use by the FDA. A story in Reuters reports that Wyeth illegally marketed its organ transplant drug Rapamune for conditions it was not approved to treat.
The charges indicated that Wyeth trained and encouraged sales representatives to promote Rapamune for uses other than preventing rejection ...
continue reading...Patient safety is greatly compromised when financial incentives interfere with crucial medical decisions. The Wall Street Journal reports how two pharmaceutical sales representatives exposed unlawful marketing practices regarding the immunosuppressant drug, Rapamune.
Pfizer and its subsidiary, Wyeth Pharmaceuticals faced a lawsuit under the Federal False Claims Act for actively marketing Rapamune for non-FDA-approved uses as well as paying kickbacks to prescribers.
In paying kickbacks to physicians, pharmaceutical companies manipulate honest and helpful medical advice. This practice could influence a doctor’s ...
continue reading...
